Samsung Life Insurance has achieved a significant pivot in its business model, with sales of health insurance now surpassing those of traditional death benefit policies. This shift marks a fundamental transformation in the company’s product portfolio, reflecting a broader strategic realignment within the South Korean insurance sector to prioritize high-margin protection products over legacy life coverage.
According to data from the Financial Supervisory Service, the company’s first-year premiums for health insurance reached 141.5 billion won last year, exceeding the 108.9 billion won generated by death insurance. First-year premiums, which represent the initial payments collected upon contract signing, are widely regarded by analysts as a primary indicator of a company’s current sales momentum and strategic direction.
For decades, Samsung Life and its peers focused heavily on whole-life and term insurance. However, the adoption of the new International Financial Reporting Standard (IFRS17) in 2023 forced a reckoning. Under these rules, the profitability of a policy is measured differently, placing a premium on “Contractual Service Margin” (CSM)—the unearned profit a company expects to realize as it provides insurance services over time.
The Profitability Gap: Why Health Insurance Wins
The drive toward 삼성생명 건강보험 판매 (Samsung Life health insurance sales) is rooted in a stark disparity in profit margins. Research from the Insurance Research Institute indicates that when applying risk-free rates under IFRS17, the margin rates for different product types vary wildly. Savings-type products offer a meager 1.2% margin, while whole-life insurance sits at 9.7%.
In contrast, health insurance—often categorized as “third-sector insurance”—boasts a margin rate of 19.1%. This means that for every won of premium collected, health insurance generates nearly double the profit of a death benefit policy. For a market leader like Samsung Life, shifting the sales mix toward health coverage is not merely a product update, but a necessity for sustaining long-term financial health.
The speed of this transition is evident in the company’s recent trajectory. At the end of 2023, shortly after IFRS17 was implemented, health insurance first-year premiums were only 49.9 billion won, dwarfed by death insurance’s 144.1 billion won. By the following year, health insurance premiums surged to 113.9 billion won, narrowing the gap before eventually overtaking death benefits in the most recent reporting cycle.
A Divergence Among the ‘Big Three’
While the entire industry is attempting this “constitution change,” Samsung Life is currently the only company among South Korea’s top three life insurers—including Kyobo Life and Hanwha Life—to successfully flip the script on death insurance sales.
| Company | Health Insurance | Death Insurance | Trend |
|---|---|---|---|
| Samsung Life | 141.5 Billion KRW | 108.9 Billion KRW | Health > Death |
| Kyobo Life | 5.5 Billion KRW | 127.2 Billion KRW | Death Dominant |
| Hanwha Life | 10.2 Billion KRW | 241.5 Billion KRW | Death Dominant |
The data highlights a significant lag for Kyobo and Hanwha, where death insurance still commands the vast majority of new business. This puts Samsung Life in a unique position of market dominance, as it has managed to pivot its massive agent network toward a more profitable product suite in a relatively short window.
The Impact on Future Earnings (CSM)
The financial implications of this pivot are most visible in the company’s Contractual Service Margin (CSM). Last year, health insurance products accounted for 2.301 trillion won of the 3.095 trillion won in new contract CSM—a staggering 75% share.
As CSM is amortized as profit over a period of seven to ten years, this current surge in health insurance sales creates a reliable “profit reservoir” for the next decade. By the end of last year, Samsung Life’s total accumulated CSM stood at approximately 13.2 trillion won, an increase of about 300 billion won compared to the previous year.
Strategic Next Steps
To maintain this momentum, Samsung Life is moving beyond generic health plans. A company spokesperson stated that the firm is focusing on enhancing the competitiveness of “pure health-centric products” and expanding tailored offerings for specific target customer groups to strengthen its grip on the comprehensive health market.
This approach involves leveraging data to create niche products that appeal to different demographics—such as aging populations requiring chronic disease management or younger generations seeking preventative wellness coverage. By diversifying the “health” umbrella, the company aims to insulate itself from the volatility of the traditional life insurance market.
Disclaimer: This article is for informational purposes only and does not constitute financial or investment advice. Insurance product margins and CSM figures are based on specific accounting standards (IFRS17) and may vary based on company-specific assumptions.
The industry will now look toward the next quarterly financial filings to see if this trend persists and if competitors can close the gap in health insurance penetration. As the market shifts toward a “living benefit” model, the ability to accurately price and sell health-related risks will define the next era of Korean life insurance.
What do you think about the shift from death benefits to health coverage? Share your thoughts in the comments or share this story with your network.
